Alpha Cognition Announces First Patient Enrolled in RESOLVE Phase 4 Study Evaluating ZUNVEYL® in Patients with Mild to Moderate Alzheimer’s Disease
Go back to Alpha Cognition Announces First Patient Enrolled in RESOLVE Phase 4 Study Evaluating ZUNVEYL® in Patients with Mild to Moderate Alzheimer’s Disease| (NASDAQ: ACOG) | Delayed: 9.03 -0.1 (1.1%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.13 | 52 Week High | $ | |||
| Open | $9.21 | 52 Week Low | $ | |||
| Day High | $9.22 | P/E | N/A | |||
| Day Low | $8.89 | EPS | $ | |||
| Volume | 9,911 | |||||
